Chen-Huang Center for EGFR-Mutant Lung Cancers

The Chen-Huang Center for EGFR-Mutant Lung Cancers aims to advance care and research of EGFR-mutant lung cancer with clinical trials of new and novel therapies supported by lab research and studies of cancer genetics.

Our trials include studies for patients with newly diagnosed EGFR-mutant lung cancer and patients whose cancer has advanced on current therapy, in addition to studies of cancer genetics.

A patient must meet certain requirements to participate in a clinical trial. Your doctor or another member of your health care team is the best resource for knowing your treatment options and eligibility.

EGFR Inhibitor Naïve

For patients that are newly diagnosed or have not yet started treatment for EGFR-mutant lung cancer:

• 18-070 – Phase II study of osimertinib with on-study and post-progression biopsies
• 21-565 – A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)
• 22-331 – A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib

EGFR Inhibitor Resistant

For patients that have had their EGFR-mutant lung cancer treated with targeted therapy already and have developed disease progression or relapse:

• 22-278 – A Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon20 Insertion Mutations
• 22-147 – A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors
• 21-540 – An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
• 21-249 – Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1 Inhibitor
• 19-368 – Phase II trial of osimertinib and novel agents
• 20-601 – Phase I Trial of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib
• 21-222 – A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
• 18-613 -- Phase 1 Study of Niraparib in Combination with Osimertinib in EGFR-Mutated Advanced Lung Cancer
• 20-465 -- A phase 1, open-label, multi-center, dose-finding, pharmacokinetic, safety and tolerability study of PF- 07265807 in participants with selected advanced or metastatic solid tumor malignancies
• 22-491 -- A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients with Active Epidermal Growth Factor Receptor Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer

EGFR Exon 20 Treatment Naïve

For patients that are newly diagnosed or have not yet started treatment for lung cancer with EGFR exon 20 insertion mutation:

• 19-280 – A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

EGFR Exon 20 Previously Treated

For patients that have had their lung cancer with EGFR exon 20 insertion mutation treated and have developed disease progression or relapse:

• 19-280 – Phase I trial of DZD9008
• 20-465 – A phase 1, open-label, multi-center, dose-finding, pharmacokinetic, safety and tolerability study of PF- 07265807 in participants with selected advanced or metastatic solid tumor malignancies
• 21-249 – A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on or are Intolerant to a PD-1/L1, EGFR, or ALK Inhibitor
• 21-540 – An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
• 22-278 -- A Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon20 Insertion Mutations